PASCONAL NERVENTROPFEN in the Treatment of Nervous Diseases (174)

Pascoe Natural Healthcare

Status: Completed

Conditions: Sleep Disorders; Nervousness

Study type: Observational

Funder types: Industry

Identifiers

NCT01125605

174A10PNAL

Details and patient eligibility

About

The purpose of this observational study is to give an overview of the use of PASCONAL NERVENTROPFEN in a 2-4 week treatment of nervous diseases, especially sleep disorders due to nervousness.

Full description

The purpose of this observational study is to give an overview of the use of PASCONAL NERVENTROPFEN in a 2-4 week treatment of nervous diseases, especially sleep disorders due to nervousness.

Efficacy and tolerability of the drug will be assessed. Special regard will be taken to the administration management, dose regimen, and to the effectiveness and safety in special patient groups (children 1-12 years of age), in relation to treatment conformity to the Summary of Product Characteristics (SmPC).

Enrollment: 325 patients

Sex: All

Ages: 1+ year old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Due to the design as an Observational Study no inclusion or exclusion criteria for therapy are named. The included patient group is described under "Cohort / Group".

Observational Criteria (=inclusion criteria for documentation):

• Males and females
• Children 1-12 years old
• Adults >12 years old
• suffering from nervous diseases, e.g. sleep disorders due to nervousness.

Exclusion criteria for documentation:

• children younger than 1 year
• no nervous diseases, e.g. sleep disorders due to nervousness.
• no treatment with PASCONAL NERVENTROPFEN

Trial design

325 participants in 3 patient groups

Adults > 12 years

Description:

adult patients and patients older than 12 years

Children 6-12 years

Description:

children between 6 and 12 years

Children 1-6 years

Description:

children between 1 and 6 years